REVB stock sentiment todayRevelation Biosciences Inc
Sentiment verdict
Gossip first, financials second — COLD at 85% confidence.
Last updated · cached analysis, refreshes periodically
REVB
Revelation Biosciences IncA micro-cap biotech struggling with extreme dilution and high-risk clinical hurdles despite recent speculative price spikes.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for REVB. Not financial advice.
Price · last 12 months
Gossip
The narrative is dominated by retail volatility and frustration over heavy dilution. While recent price action shows a 7% bounce, the long-term sentiment is scarred by a massive 1-for-30 reverse split earlier in 2024 and frequent capital raises that wipe out equity holders.
- ·Speculation on Gemini clinical trial data
- ·History of massive share dilution
- ·Low float volatility attracting day traders
- ·Lack of institutional conviction
Financial
REVB is a pre-revenue clinical-stage company with a precarious balance sheet. While they raised capital recently to fund the Gemini Phase 1b trial, their cash burn remains high relative to their market cap, and they lack a commercialized product to offset losses.
- ·Net Loss: Significant annual operating losses
- ·Revenue: $0 (Pre-revenue)
- ·Current Ratio: Temporarily stabilized by recent offerings
- ·Market Cap: Micro-cap (Highly illiquid)
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Hollow — insiders are stepping back and the register is short-horizon.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Clinical failure of lead candidate Gemini
- ·High probability of further equity dilution to fund operations
- ·Delisting risk if price falls back below NASDAQ minimums
- ·Extreme volatility due to low share float
Peer temperature
How direct competitors stack up against REVB right now.
- NEUTRALVaxart (VXRT)Vaxart Inc.
HOTTER — possesses a more advanced oral vaccine platform and significantly higher institutional ownership compared to REVB's early-stage pipeline.
See full analysis → - HOTAltimmune (ALT)Altimmune Inc.
HOTTER — maintains a much stronger cash position and higher-conviction assets in the obesity (GLP-1) space, offering better risk-adjusted upside.
See full analysis → - NEUTRALAcurx Pharmaceuticals (ACXP)Acurx Pharmaceuticals
NEUTRAL — similarly speculative micro-cap, but offers a more focused approach on antibiotic-resistant infections with more consistent Phase 2 data flow.
See full analysis →
- REVB-29.5%
- Vaxart (VXRT)—
- Altimmune (ALT)—
- Acurx Pharmaceuticals (ACXP)—
Analyst price target
Consensus average of 1 analyst · median 16.00
Source: StockAnalysis.com · updated 2026-08-07
AI-generated analysis for informational purposes only. Not financial advice.